Genmab has announced promising results from the Phase 1b/2 EPCORE® NHL-2 trial, which evaluated a fixed-duration regimen of epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular…
Genmab has announced promising results from the Phase 1b/2 EPCORE® CLL-1 clinical trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). Epcoritamab, administered subcutaneously as monotherapy, demonstrated an overall response…
Stoke Therapeutics has announced new data from its Phase 1/2a and open-label extension (OLE) studies on zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The data revealed significant and lasting reductions in convulsive seizure frequency in patients who received zorevunersen…
Alithea Genomics, a leading innovator in large-scale RNA sequencing and transcriptomics, has unveiled its latest technological advancement: the MERCURIUS™ Full-Length DRUG-seq library preparation platform. This new solution represents a groundbreaking approach in RNA sequencing, combining massive sample multiplexing, an extraction-free…
At Children’s Hospital Los Angeles Dr. Aaron Nagiel, MD, PhD, has witnessed firsthand the profound impact of retinal gene therapy on children with Leber congenital amaurosis (LCA), a rare genetic disorder that causes severe vision loss. Though visual progress is…
BeiGene a global leader in oncology, has announced a new partnership with the CLL Society, the premier authority for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cancer patients. Together, they are advancing the Test Before Treat™ campaign, an…
The World Health Organization (WHO) has granted prequalification to the Xpert® MTB/RIF Ultra molecular diagnostic test, making it the first tuberculosis (TB) diagnostic and antibiotic susceptibility test to meet WHO’s stringent prequalification standards. This marks a pivotal step toward enhancing…
Novo Nordisk has announced that 13 abstracts from its research will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California, from December 7 to 10, 2024. Of these, three…
Ipsen and Biomunex Pharmaceuticals have entered into an exclusive global licensing agreement for BMX-502, a promising bispecific antibody designed to target and activate Mucosal-Associated Invariant T cells (MAIT cells) to combat cancer. BMX-502 is specifically engineered to target the GPC3…
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company dedicated to central nervous system (CNS) therapeutics, has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). The application seeks approval for CAPLYTA…
Ono Pharmaceutical Co., Ltd. (Ono), headquartered in Osaka, Japan, has entered into a strategic collaboration agreement with Congruence Therapeutics, a biotechnology company based in Montreal, Canada. This partnership aims to develop innovative small molecule correctors targeting key proteins in the…
Daiichi Sankyo will present over 45 abstracts highlighting the progress across its oncology portfolio at the 2024 ESMO Asia Congress,San Antonio Breast Cancer Symposium and The American Society of Hematology Annual Meeting. The research spans a variety of solid and…